Showing papers by "Scott M. Grundy published in 2022"
TL;DR: In this paper , the authors provide insights to help clinicians identify and address high-risk conditions in the 20- to 39-year age range (young adults) to predict early-onset atherosclerotic cardiovascular disease (ASCVD).
43 citations
TL;DR: The authors compared the US Preventive Services Task Force (USPSTF) recommendations with the American Heart Association/American College of Cardiology (AHA/ACC)/multisociety guidelines on statin usage in primary prevention.
Abstract: This Editorial compares the US Preventive Services Task Force (USPSTF) recommendations with the American Heart Association/American College of Cardiology (AHA/ACC)/multisociety guidelines on statin usage in primary prevention.
5 citations
TL;DR: In this paper , the success of guideline implementation depends on the consideration of a variety of barriers that exist throughout the healthcare delivery system, and further research is needed to comprehensively evaluate these barriers in order to develop appropriate and sustainable interventions to improve guideline implementation.
3 citations
TL;DR: Baigent et al. as mentioned in this paper conducted a meta-analysis of data from 170,000 participants in 26 randomised trials and concluded that statin therapy has potential to markedly reduce risk for atherosclerotic cardiovascular disease (ASCVD).
1 citations
TL;DR: The pooled-cohort equation (PCE) as discussed by the authors has been verified in a natural history cohort, but the reliability of the equation in contemporary US subpopulations has been debated for those in the intermediate range of risk.
Abstract: Quantification of risk for atherosclerotic cardiovascular disease (ASCVD) is important. Traditional risk assessment begins with numerical estimation. The pooled-cohort equation (PCE), as described in the 2018 American Hospital Association/American College of Cardiology/MultiSociety guidelines, serves as the basis for 10-year ASCVD-risk estimation.1,2 Although the PCE has been verified in a natural history cohort, the reliability of the equation in contemporary US subpopulations has been debated for those in the intermediate range of risk.
TL;DR: In this paper , the authors suggest that accuracy can be improved by measurement of coronary artery calcium (CAC), which has the advantage of identifying men at low risk in whom statin therapy can be delayed for several years, provided they are monitored periodically for progression of CAC.